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Objectives: Adenovirus-mediated gene therapy has been proposed as a
potential treatment modality in lung transplantation. However, to date
its utility has been limited by an inflammatory host immune response
that not only limits the amount and duration of transgene expression
but also obviates successful retransfection. Having previously shown
that by administering triple-immunosuppression, as is routine in lung
transplantation, we could increase and prolong transgene expression
after initial transfection, we hypothesized that transgene expression
after retransfection could also be increased and prolonged. Methods:
Lewis rats underwent intratracheal adenovirus-mediated transfection
with the b -galactosidase gene and were randomized to either the
immunosuppression group, receiving daily cyclosporine (INN: ciclo-
sporin), azathioprine, and methylprednisolone, or the control group (no
immunosuppression). Five weeks later, rats were similarly retransfected
and transgene expression and post-transfection inflammation were eval-
uated 1, 7, and 14 days after retransfection. Results: After retransfection,
immunosuppressed rats had significantly higher levels of transgene
Stephen D. Cassivi, MD, MSca
Mingyao Liu, MD, MSca
Annette Boehler, MDa
A. Keith Tanswell, MB, BSb
Arthur S. Slutsky, BASc, MASc, MDc
Shaf Keshavjee, MD, MSca
Sponsor: Thomas R. J. Todd, MD
1
From the Thoracic Surgery Research Laboratory, Division of
Thoracic Surgery, The Toronto Hospital Research Institute,a
Medical Research Council Group in Lung Development,
Department of Paediatrics, The Hospital for Sick Children,b and
Division of Respiratory Medicine, Mount Sinai Hospital,c
University of Toronto, Toronto, Ontario, Canada.
This work was supported by a grant from the National Sanitarium
Association of Canada. Dr Liu is a scholar of the Medical
Research Council of Canada. Dr Boehler is a recipient of grants
from the Swiss National Scientific Foundation and the Swiss
Respiratory Society.
Read at the Seventy-eighth Annual Meeting of The American
Association for Thoracic Surgery, Boston, Mass, May 3-6, 1998.
Received for publication April 6, 1998; revisions requested June 23,
1998; revisions received July 24, 1998; accepted for publication
Sept 8, 1998.
Address for reprints: Shaf Keshavjee, MD, Division of Thoracic
Surgery, The Toronto Hospital, EN-10-224, 200 Elizabeth St,
Toronto, Ontario, Canada M5G 2C4.
J Thorac Cardiovasc Surg 1999;117:1-7
Copyright © 1999 by Mosby, Inc.
0022-5223/99 $8.00 + 0 12/6/94277






TRANSGENE EXPRESSION AFTER ADENOVIRUS-MEDIATED RETRANSFECTION OF RAT LUNGS IS
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With overall survivorships of only 70% and 60% at12 and 24 months, respectively, significant
improvements to the lung transplantation process can
and must be developed.1 Together, early graft dysfunc-
tion resulting from ischemia-reperfusion injury and
chronic lung dysfunction, as manifested by progressive
obliterative bronchiolitis, account for the major part of
mortality and significant morbidity after lung trans-
plantation.1,2 In particular, obliterative bronchiolitis
occurs in almost 50% of lung transplant recipients sur-
viving at least 3 months after transplantation and car-
ries a 4-fold increase in relative risk of mortality.3
There remains, however, no known effective prevention
or treatment for this post-transplantation syndrome.
Adenovirus-mediated gene therapy, with its ability to
modify transfected somatic cells, has been suggested as
a treatment option for a number of diseases and injuries
including reperfusion injury and obliterative bronchi-
olitis.4,4a Gene therapy presents the possibility of modi-
fying the transplanted lung in a number of potentially
beneficial ways. This could be achieved, for example,
either through up-regulation of protective endogenous
antioxidants at the time of transplantation to counter-
act ischemia-reperfusion injury or by the delivery of an
anti-inflammatory cytokine gene, such as interleukin-
10 to forestall or prevent the onset of obliterative
bronchiolitis.4
The potential of gene therapy has been severely lim-
ited, however, by a significant inflammatory host im-
mune response. Transfected cells are directly targeted
and destroyed by cytotoxic T lymphocytes, with virtu-
ally no transgene expression detectable by 14 to 21
days after transfection (unpublished data).5-9 This
immune response has been shown to be even stronger
after repeated administration of the vector-gene con-
struct. After adenovirus-mediated retransfection, an
almost immediate anamnestic response is seen, causing
transgene expression levels to be virtually nonexis-
tent.6,9-11 These immunologic obstacles to effective
gene transfer have heretofore seriously limited any
practical clinical application of gene therapy.
Inasmuch as transplant recipients are necessarily
immunosuppressed after surgery to prevent organ
rejection, we hypothesized that immunosuppression, as
used in the transplant setting, could attenuate the dele-
terious immune reaction after transfection. In a previ-
ous study, we demonstrated this concept in a rat model
after a 1-time adenovirus-mediated transfection. Not
only was transgene expression increased significantly,
but these elevated levels were prolonged to 5 weeks
after transfection.4a
For gene therapy to be made clinically feasible, espe-
cially for such chronic and long-term injuries as obliter-
ative bronchiolitis, it is essential to further demonstrate
the ability to effectively retransfect the transplant recip-
ient. In this study, we therefore investigated the ability
of transplant immunosuppression to attenuate the severe
immune response to retransfection and achieve
increased and prolonged transgene expression levels.
Material and methods
Gene delivery and immunosuppression. Male Lewis rats
(275-300 g; Harlan Sprague Dawley, Inc, Indianapolis, Ind)
were anesthetized by intraperitoneal injection of ketamine
(Rogar; London, Ontario, Canada) and acepromazine (Ayerst;
Montreal, Quebec, Canada) and intubated with a 16-gauge
Teflon angiocatheter (Becton-Dickinson, Sandy, Utah). They
were then transfected intratracheally with 109 pfu of E1-delet-
ed type 5 adenovirus containing the lacZ gene with a
cytomegalovirus promoter (Ad5CMVlacZ; University of Iowa
Gene Transfer Vector Core, Iowa City, Iowa) in 200 m L of
0.3% sucrose in phosphate-buffered saline (PBS) solution.
After transfection, rats underwent simple randomization to
either immunosuppressed or nonimmunosuppressed (control)
groups (n = l2 and 17 per group, respectively). Starting on the
day of transfection, immunosuppressed rats received daily
intraperitoneal injections of cyclosporine (INN: ciclosporin)
(15 mg/kg per day; Sandoz, Dorval, Quebec, Canada), aza-
thioprine (6 mg/kg per day; Burroughs Wellcome, Kirkland,
Quebec, Canada), and methylprednisolone (2.5 mg/kg per
day; Upjohn, Don Mills, Ontario, Canada). Five weeks after
initial transfection, rats from both groups were administered a
second dose of the gene-vector construct.
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expression (P < .001), whereas control rats had virtually no detectable
levels. On histologic sections of the lungs, immunosuppressed rats had
overall lesser grades of post-transfection inflammation. Conclusions:
Transplant immunosuppression attenuates the severe immune response
to gene transfer and permits increased, prolonged, and repeated trans-
fection. Retransfection is now achievable in the immunosuppressed
lung transplant setting to allow for chronic, repeated administration of
gene therapy. (J Thorac Cardiovasc Surg 1999;117:1-7)
Lung excision. On days 1, 7, and 14 after retransfection,
rats from both immunosuppressed (n = 3, 4, and 5, respec-
tively) and control (n = 5, 6, and 6, respectively) groups were
randomly chosen for sacrifice and evaluation of transgene
expression. Rats were anesthetized with pentobarbital (MTC
Pharmaceuticals, Cambridge, Ontario, Canada) and ventilat-
ed via a tracheostomy (Harvard rodent ventilator model 683,
Harvard Apparatus Co, South Natick, Mass). Lungs were
flushed via the pulmonary artery with 20 mL of 0.9% saline
solution at 20 cm H2O pressure before en bloc excision.
Samples from each of the 4 lobes of the right lung were then
sectioned and snap frozen in liquid nitrogen for subsequent
determination of b -galactosidase transgene expression by
cellular chemiluminescence. The left lung was processed for
chromogenic staining and histologic sectioning.
Cellular chemiluminescence. b -Galactosidase transgene
expression in the lung tissue was measured by the Galacto-
light cellular chemiluminescence assay (Tropix, Bedford,
Mass).12 Lung sections were individually homogenized and
sonicated in 5 mL of PBS and 200 m L lysis solution. After
centrifugation, the supernatant samples were incubated with
reaction buffer for 1 hour before the addition of the accelera-
tor solution. Samples were measured in relative light units by
means of a standard chemiluminometer (Berthold, Bad
Wildbad, Germany) and standardized to each sample’s pro-
tein content as measured by the Bradford assay technique.13
Chromogenic staining. After excision, left lungs were
perfused via the trachea with standard fixative: 4% formal-
dehyde, 0.2% glutaraldehyde, and a 2 mmol/L concentration
of MgCl2 in PBS. One hour later, the fixative was washed out
with PBS. The chromogenic substrate for b -galactosidase, 5-
bromo-4-chloro-3-indolyl- b -D-galactopyranoside (X-Gal;
Sigma Chemical Co, St Louis, Mo), in a staining solution (5
mmol/L K3Fe(CN)6, 5 mmol/L K4Fe(CN)6, 2 mmol/L
MgCl2, 0.05% Triton X-100, in PBS), was then instilled into
the lungs and allowed to incubate overnight at 37°C.4a Lungs
were then sectioned and embedded in paraffin blocks.
Histologic grading. Mid-sagittal slices of the left lung,
stained with hematoxylin and eosin, were used to permit
blinded histologic assessment and histopathologic grading of
the inflammatory response to adenoviral transfection. A mod-
ification of the grading method developed by Ginsberg and
colleagues14 to characterize mouse and cotton rat models of
adenoviral pneumonia was used. For each specimen, the fol-
lowing 4 criteria were assessed: airway epithelial injury and
peribronchial, perivascular, and alveolar space inflammation.
These criteria were graded on a scale ranging from normal
appearance to minimal (<25%), mild (25%-50%), moderate
(50%-75%), and severe (>75%) abnormalities and scored
from 0 to 4, respectively.
Animal care. The investigational protocol was reviewed
and approved by the Toronto Hospital Research Institute
Animal Care and Biohazard committees. All animals
received humane care in compliance with the “Principles of
Laboratory Animal Care” formulated by the National Society
for Medical Research, the “Guide for the Care and Use of
Laboratory Animals” prepared by the National Academy of
Science and published by the National Institutes of Health
(NIH publication No. 85-23, revised 1985), and the “Guide to
the Care and Use of Experimental Animals” formulated by
the Canadian Council on Animal Care.
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Fig 1. b -Galactosidase transgene expression is increased and prolonged in the lungs of immunosuppressed rats.
As compared with control rats, which show virtually no detectable transgene expression, rats receiving transplant
immunosuppression have a significantly higher level and persistence of elevated transgene expression as far as 2
weeks after retransfection. Overall difference between the 2 groups, as assessed by 1-way analysis of variance, is
significant with a P value less than .001. RLU, Relative light units; ng, nanograms; error bars indicate standard
deviation.
Statistical analysis. Differences between immunosup-
pressed and nonimmunosuppressed b -galactosidase transgene
expression by chemiluminescence were analyzed by means of
2-tailed, unpaired Student t tests adjusted for unequal vari-
ances and for multiple comparisons by means of the
Bonferroni correction. One-way analysis of variance was used
to test for overall difference between the immunosuppressed
and control groups. Kruskal-Wallis tests were performed to
assess statistical differences between immunosuppressed and
control groups for the nonparametric histologic grading
scores. Individual time points were assessed for statistically
significant differences using Dunn’s post-hoc analysis. Data
were analyzed with the SigmaStat version 1.0 statistical soft-
ware package (Jandel Scientific, San Rafael, Calif).
Results
Quantitative transgene expression. After repeat
transfection, immunosuppressed rats had significantly
elevated transgene expression at all 3 evaluated time
points: days 1, 7, and 14 after retransfection (P < .001;
Fig 1). In contrast, transgene expression was virtually
undetectable at all time points in control rats. As with
initial transfection, seen in our earlier studies,4a peak
levels of transgene expression were noted at day 7.
Chromogenic tissue staining. Rat lung blocks,
stained with X-Gal to demonstrate the presence of b -
galactosidase transgene, showed positive and diffuse
staining in lungs from rats in the transplant immuno-
suppression group at the 1-, 7-, and 14-day time points.
Corresponding lung blocks from the control (nonim-
munosuppressed) group failed to show any detectable
positive staining at any of the tested time points after
retransfection (Fig 2).
Post-transfection inflammation. Grading of lung
tissue sections for post-transfection inflammation
revealed several notable results. Alveolar inflammation
in the control group was significantly more severe than
in the immunosuppressed group and was present from
day 1 after retransfection (Fig 3, A; P = .004).
Infiltrating cells were found within the alveolar air
space and interstitium and continued to be observable
at days 7 and 14 in the control group. Peribronchial
inflammation was also more severe in the control group
(P = .002) and was observable as early as day 1 after
retransfection (Fig 3, B). Inflammation involving the
perivascular space was also significantly higher in the
control group (P = .03) and was readily apparent at the
day 1 time point (Fig 3, C). Airway epithelial cell
injury was apparent only in the immunosuppressed
group on day 1 after retransfection and only to a mild
degree (Fig 3, D). By day 7, evidence of airway epithe-
lial regeneration was observable and no further injury
was noted. Control animals showed no airway epithe-
lial injury throughout the time course of this study.
Discussion 
While conventional forms of therapy aim to alter
function through transient exposure to external agents,
such as medications, the ultimate goal of gene therapy
is to effect sustained modifications in structure or func-
tion of cells and organs by the transformation of the
host’s genetic composition. A fundamental step in the
process of applying gene therapy, in both the experi-
mental and clinical settings, is the successful transfer of
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Fig 2. Chromogenic staining of rat lung blocks demonstrates
positive and prolonged parenchymal expression of b -galac-
tosidase transgene in immunosuppressed rats after retransfec-
tion. Whereas lung tissue from the nonimmunosuppressed
group fails to show positive X-Gal staining after retransfec-
tion, lungs from rats receiving transplant immunosuppression
demonstrate positive b -galactosidase staining at the 1-, 7-,
and 14-day time points.
new genetic material to the target cells. Previous studies
have emphasized the immune host reaction to transfec-
tion as a major obstacle to successful gene transfer after
both initial transfection and repeated transfection.4-11
In particular, retransfection, as a means to provide
repeated long-term gene therapy, has been significant-
ly limited by this immune response. The inability to
effectively retransfect is believed to be due to neutral-
izing antibodies, produced by B cells in response to
class II major histocompatibility complex presentation
of input viral proteins.5,9-11 Further studies have
demonstrated that, in addition to this humoral compo-
nent, there is an associated cell-mediated effect from
CD4+ T cells that plays a role in the neutralizing
immune activity.10,15
In keeping with the results of these previous studies of
repeated adenovirus-mediated transfection, our results in
nonimmunosuppressed (control) rats show the same
type of anamnestic immune response with virtually no
detectable transgene expression at any of the tested time
points after retransfection. This was tested both by quan-
titative chemiluminescence assays and by chromogenic
tissue staining. Our findings demonstrate, however, that
the inability, to date, to successfully retransfect lung tis-
sue can be overcome by the administration of triple
immunosuppression of the type used in transplantation.
Levels of transgene expression in the immunosup-
pressed lungs, in our study, were not only significantly
increased over those of the control group, but they were
also prolonged out to 2 weeks after retransfection.
The peak of transgene expression, noted at day 7 in
the immunosuppressed group, is consistent with the
peak seen after initial transfection by the intratracheal
route.4a The levels of transgene expression in the
immunosuppressed group after retransfection in this
study did not reach the peak levels seen in our previous
study of 1-time transfection with similar transplant
immunosuppression. However, they did surpass and in
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Fig 3. Pathologic grading of post-retransfection inflammation in histologic sections of rat lungs shows overall
decreased inflammation in the immunosuppressed group. Lung sections from each of the tested time points were
stained with hematoxylin and eosin, and inflammation was graded in the following 4 categories: A, Alveolar
inflammation; B, peribronchial inflammation; C, perivascular inflammation; D, epithelial cell damage. †P < .05
between immunosuppressed and control groups overall; *P < .05 between immunosuppressed and control groups
at specified time points.
fact showed more than a 2-fold increase over the
decreasing levels seen in immunosuppressed rats at 5
weeks after initial transfection. It should be further
noted that transplant immunosuppression may show
even higher transgene expression levels when transfect-
ing with vectors expressing less immunogenic transgene
products than the highly immunogenic, foreign b -galac-
tosidase used in this study.15
Levels of inflammation, as assessed by histologic
grading, were notably higher in the nonimmunosup-
pressed animals. These animals had patterns of inflam-
mation consistent with previous studies of adenovirus-
mediated retransfection.9 In contrast to the control
group, lungs from the immunosuppressed group show
significantly attenuated levels of inflammatory infil-
trate. When compared with the amount and type of
inflammation seen after 1-time transfection,4a the
inflammation seen in nonimmunosuppressed lungs
after retransfection was both earlier in onset and of a
more intense nature. This is in keeping with the more
rapid and profound immune reaction attributed to the
anamnestic response seen in previously sensitized
hosts. Of particular note is the early appearance of alve-
olar inflammation in the control group after retransfec-
tion. The onset of this type of inflammation coincides
temporally with the loss of transgene expression after
both initial transfection (days 7-144a) and retransfection
(day 1) and may serve as a signal that transgene expres-
sion has been arrested.
Clearly, attenuation of the immune response to aden-
ovirus-mediated transfection continues to be a major
focus for those interested in the clinical application of
gene therapy. However, the administration of immuno-
suppression combined with gene therapy in the treat-
ment of such chronic lung diseases as cystic fibrosis
and emphysema is limited by the very nature of these
diseases, which predispose patients to frequent and
often life-threatening infections. Fortunately, the set-
ting of lung transplantation, where patients necessarily
receive immunosuppression to prevent rejection of the
transplanted organ, provides an excellent opportunity
for the successful application of gene therapy. As we
progress closer to clinical trials of gene therapy in the
transplant setting, it will be important to pay particular
attention to the clinical grade of viral vector with spe-
cial emphasis on the issue of viral replication deficiency.
Clearly, what is currently termed replication deficient
has retained the potential for viral replication, at least to
some degree. The impact of this issue, especially in the
context of immunosuppressed patients, will have to be
determined.
Enhanced and prolonged adenovirus-mediated gene
therapy using transplant immunosuppression has been
demonstrated, with transgene levels lasting more than 1
month after transfection.4a Indeed, the lungs present a
unique opportunity among transplantable organs in that
they provide an easily accessible and relatively nonin-
vasive route via the trachea for local readministration
of adenoviral gene therapy. The ability of transplant
immunosuppression to attenuate the immune response
to retransfection and produce effective and prolonged
transgene expression after repeated vector administra-
tion, as shown in this study, further increases the clini-
cal practicality of gene therapy in lung transplantation,
particularly for the prevention or attenuation of such
complications as obliterative bronchiolitis.
We are grateful Dr Brendan Mullen of the department of
Pathology and Laboratory Medicine, Mount Sinai Hospital,
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Discussion
Dr Andrew S. Wechsler (Philadelphia, Pa). It is easy to
understand why you would have enhanced expression of your
transgene in the group that was subjected to retransfection.
However, I always thought a fairly rapid transfection would
occur on first exposure to an adenovirus. Could you postulate
about how the immunosuppression facilitated increasing the
expression of the adenovirus on the first exposure?
Dr Cassivi. That question is best illustrated if I return to
the initial transfection results. 
The initial rise of transgene expression in both the im-
munosuppressed and nonimmunosuppressed groups is virtu-
ally the same. It is only at 7 days, once the transgene expres-
sion starts to tail off in the control group, that a significant
improvement in the transgene expression in the immunosup-
pressed group can be seen. I believe that is the effect of the
immunosuppression in attenuating the immune response.
With the adenoviral transfection occurring epichromosomally
and the immune response attacking transfected cells, those
cells that have escaped attack by the protective immunosup-
pression are able to continue to express the transgene.
Dr Todd Rosengart (New York, NY). I certainly agree with
you. There are a number of studies that now show that aden-
ovirus is influenced by immunosuppression. In fact, there are
alternative strategies as well using different serotypes to cir-
cumvent the immune-mediated down-regulation of adenovirus
expression. 
One important point, as these data become more wide-
spread, is that inflammation appears to be related to the
amount of replication-competent particles. When we used
clinical-grade vector, where there are essentially no replica-
tion-competent particles, we found little inflammation. On the
other hand, when using preparations with higher replication-
competent adenovirus levels, we found much more inflamma-
tion. What was the quality of your vector preparation? 
My second point is that other strategies will be developed,
besides immunosuppression, for prolonging adenovirus
expression or gene therapy expression, such as the use of
adeno-associated virus. Have you looked at vectors other than
adenovirus in your studies?
Dr Cassivi. We used the first-generation adenovirus, an
E1-deleted replication-deficient or supposedly replication-
deficient viral vector. With continued research we found that
the nomenclature of replication deficiency may not be
absolutely correct. Replication deficiency of these E1-deleted
vectors depends on the cell type being transfected. In an
already dividing cell, those functions deleted from the E1
region may already be provided, allowing the virus to escape
this control and be replication-competent.
We decided to use the most primitive form of adenoviral vec-
tor to prove the principle that immunosuppression in the trans-
plant setting was advantageous for adenoviral transfection. In
the future, with advances that are continuing to be made in the
construction and development of vectors, such as the adeno-
associated vector, we may be able to achieve even better results
and make these findings much more widely applicable. 
Dr Alain F. Carpentier (Paris, France). I have 2 brief
questions. First, how long should you prolong your immuno-
suppression? Does the transgene expression persist when you
stop the immunosuppression? Second, have you tried any of
the immunosuppressive agents separately so as to eventually
have a less aggressive therapy? 
Dr Cassivi. We tried to mimic the clinical setting in lung
transplantation using the triple immunosuppression of
cyclosporine, azathioprine, and methylprednisolone. We did
not halt the immunosuppression, because our transplant
patients necessarily receive life-long immunosuppression to
prevent graft rejection. That was the hypothesis and design of
our studies.
As an answer to your second question, we did not do sepa-
rate studies. It would be useful to investigate the individual
effects on transgene expression of the 3 different immuno-
suppressants used currently and maybe the newer immuno-
suppressants that are now being used in transplantation. 
Dr Robert C. Robbins (Stanford Calif). Is this an isograft
model or an allograft model? 
Dr Cassivi. These experiments were done in nontrans-
planted rats. They received transplant immunosuppression at
the time of transfection. We are now starting to examine thera-
peutic gene administration in a rat single-lung transplant model. 
Dr Robbins. Have you used surfactant to increase your
transfection efficiency? When we have tried this in rat lungs,
we have not been able to transfect them very well, but with
surfactant we were able to improve the transfection efficiency. 
Dr Cassivi. We did not use any surfactant to improve the
distribution. If you refer to the photographs of the lung blocks
stained with X-Gal from the retransfection group, you can see
that there is a fairly diffuse and generalized staining of the
lung, demonstrating the diffuse distribution of transfection.
Furthermore, we did do studies in the right lung, which has 4
lobes in the rat, and quantitatively there was no significant
difference between the transgene expression levels in any of
the 4 right lung lobes.
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